(Total Views: 139)
Posted On: 09/05/2020 8:02:49 AM
Post# of 4861
Excellent Ulf53 . Cardiol CBD (CRTPF) President and CEO David Elsley joined Steve Darling from Proactive Vancouver with news the company has initiated their Health Canada approved Phase 1 clinical study of CardiolRx.
David Elsley indicated the study will be a double-blind, placebo-controlled, randomized study to assess safety, tolerability, and pharmacokinetics of single and multiple day doses of CardiolRx.
https://www.youtube.com/watch?v=3f_HbuwGPuI&t=96s
I love it when a company is not afraid to communicate with its shareholders and the world.
Kgem
David Elsley indicated the study will be a double-blind, placebo-controlled, randomized study to assess safety, tolerability, and pharmacokinetics of single and multiple day doses of CardiolRx.
https://www.youtube.com/watch?v=3f_HbuwGPuI&t=96s
I love it when a company is not afraid to communicate with its shareholders and the world.
Kgem
(2)
(0)
